Tag Archives: Puma Biotechnology

April 2020—The FDA approved neratinib (Nerlynx, Puma Biotechnology) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the metastatic setting.

Read More »